$NUKK
Nukkleus Inc. Stock $nukk

$nukk Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023068964 Filed on August 18, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue		$5.370M	$5.431M
YoY Change		-1.03%	-5.25%
Gross Profit		-$158.0K	-$54.87K
YoY Change		-42.23%	-90.91%
Gross Profit Margin
Selling, General & Admin		$988.5K	$1.015M
YoY Change		-24.81%	-20.36%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$592.9K	$592.9K
YoY Change		0.0%	-34.99%
% of Gross Profit
Operating Expenses	$116.7K	$120.0K	$107.7K
YoY Change	-75.74%	-17.01%	-73.78%
Operating Profit	-$116.7K	-$123.7K	-$162.5K
YoY Change	-75.74%	-14.41%	-83.97%
Interest Expense	-$9.390K	$0.00	$214.6K
YoY Change	-90.41%	-100.0%	-1066.85%
% of Operating Profit
Other Income/Expense, Net	-$9.394K	$1.385K	$2.570K
YoY Change	-90.4%	-98.73%	-310.66%
Pretax Income	-$126.1K	-$120.0K	$107.0K
YoY Change	-78.22%	237.65%	-124.72%
Income Tax		$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$126.1K	-$122.4K	$107.0K
YoY Change	-78.22%	244.26%	-124.72%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.07	-$0.06	-$0.11
Diluted Earnings Per Share	-$0.07	-$0.06	$0.02
COMMON SHARES
Basic Shares Outstanding	1.815M shares	1.816M shares	2.076M shares
Diluted Shares Outstanding	1.914M shares	1.916M shares	10.07M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.608M	$4.597M	$6.111M
YoY Change	-85.23%	-88.95%	-87.18%
Cash & Equivalents	$4.608M	$4.597M	$6.111M
Short-Term Investments
Other Short-Term Assets	$32.52K	$0.00	$740.00
YoY Change	-37.43%	-100.0%	-99.97%
Inventory
Prepaid Expenses
Receivables		$189.2K	$102.8K
Other Receivables	$2.039M	$0.00	$0.00
Total Short-Term Assets	$4.608M	$4.597M	$6.112M
YoY Change	-85.26%	-88.97%	-87.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$391.2K	$6.602M	$6.602M
YoY Change	-94.07%	-41.06%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$4.608M	$4.597M	$6.112M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$4.608M	$4.597M	$6.112M
YoY Change	-85.26%	-88.97%	-87.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$138.7K	$470.0K	$315.0K
YoY Change	-58.83%	316.29%	1.75%
Accrued Expenses		$450.2K	$424.9K
YoY Change		-2.66%
Deferred Revenue
YoY Change
Short-Term Debt	$4.181M	$4.030M	$3.651M
YoY Change	20.05%	37.54%	124.62%
Long-Term Debt Due	$17.50K
YoY Change
Total Short-Term Liabilities	$4.651M	$4.504M	$3.966M
YoY Change	21.77%	48.01%	104.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$19.58K	$10.00K	$10.64K
YoY Change	-91.31%	-91.6%	-94.1%
Total Long-Term Liabilities	$422.4K	$10.00K	$10.64K
YoY Change	87.5%	-91.6%	-94.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.651M	$4.504M	$3.966M
Total Long-Term Liabilities	$422.4K	$10.00K	$10.64K
Total Liabilities	$4.671M	$4.514M	$3.976M
YoY Change	15.47%	42.76%	87.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.550M	-$8.327M	-$7.800M
YoY Change	9.06%	20.69%	36.55%
Common Stock	$3.880M	$3.880M	$3.880M
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.669M	-$4.447M	-$3.920M
YoY Change
Total Liabilities & Shareholders Equity	$4.608M	$4.597M	$6.112M
YoY Change	-85.26%	-88.97%	-87.18%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	-$126.1K	-$122.4K	$107.0K
YoY Change	-78.22%	244.26%	-124.72%
Depreciation, Depletion And Amortization		$592.9K	$592.9K
YoY Change		0.0%	-34.99%
Cash From Operating Activities	-$121.0K	-$70.00K	-$78.25K
YoY Change	-14.04%	-67.37%	-64.82%
INVESTING ACTIVITIES
Capital Expenditures		$460.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	132.0K	210.0K	-25.01M
YoY Change	-101.3%	110.0%	-1910.57%
NET CHANGE
Cash From Operating Activities	-121.0K	-70.00K	-78.25K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	132.0K	210.0K	-25.01M
Net Change In Cash	11.05K	140.0K	-25.09M
YoY Change	-99.96%	-222.25%	11256.1%
FREE CASH FLOW
Cash From Operating Activities	-$121.0K	-$70.00K	-$78.25K
Capital Expenditures		$460.00
Free Cash Flow		-$70.46K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1915531	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1932251	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5477208	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5755372	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39341
	dei	Entity Registrant Name EntityRegistrantName	BRILLIANT ACQUISITION CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	D8
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Floor 20-21
	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 55 Loushanguan Road
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Changning District
	dei	Entity Address City Or Town EntityAddressCityOrTown	Shanghai
	brli	Redemption Of Share3 RedemptionOfShare3	159203	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6110807	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	738	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	4597048	usd
	dei	Entity Address Country EntityAddressCountry	CN
	dei	City Area Code CityAreaCode	(86)
	dei	Local Phone Number LocalPhoneNumber	021-80125497
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1814696	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4597048	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6111545	usd
CY2023Q2	us-gaap	Assets Assets	4597048	usd
CY2022Q4	us-gaap	Assets Assets	6111545	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	474320	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	315023	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1165600	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	970600	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2863927	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2680227	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4503847	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3965850	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10183	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10643	usd
CY2023Q2	us-gaap	Liabilities Liabilities	4514030	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3976493	usd
CY2023Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	405475	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	564936	shares
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4529548	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	6055016	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1511000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1511000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1511000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1511000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	3880288	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3880288	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8326818	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7800252	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4446530	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3919964	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4597048	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6111545	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	123748	usd
CY2022Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	144590	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	343326	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	613861	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-123748	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-144590	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-343326	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-613861	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1385	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-56342	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-460	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-61383	usd
CY2022Q2	us-gaap	Interest Income Other InterestIncomeOther	52704	usd
	us-gaap	Interest Income Other InterestIncomeOther	56652	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1385	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	109046	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	460	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	118035	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-122363	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-35544	usd
	us-gaap	Net Income Loss NetIncomeLoss	-342866	usd
	us-gaap	Net Income Loss NetIncomeLoss	-495826	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1915531	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5477208	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1932251	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5755372	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4226817	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-122363	usd
CY2023Q2	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-97350	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4446530	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3919964	usd
	us-gaap	Net Income Loss NetIncomeLoss	-342866	usd
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-183700	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4446530	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2930830	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-35544	usd
CY2022Q2	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-52704	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3019078	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1832006	usd
	us-gaap	Net Income Loss NetIncomeLoss	-495826	usd
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-687298	usd
	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-3948	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3019078	usd
	us-gaap	Net Income Loss NetIncomeLoss	-342866	usd
	us-gaap	Net Income Loss NetIncomeLoss	-495826	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-460	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-61383	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	56652	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-738	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	103213	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	159297	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-196695	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-183291	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-913769	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	634594	usd
	brli	Proceeds From Sale Of Investment Of Cash In Trust Account ProceedsFromSaleOfInvestmentOfCashInTrustAccount	6529259	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5894665	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	195000	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	670100	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	183700	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	634594	usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	1709168	usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	6529259	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1330468	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5224565	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1513759	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-243669	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6110807	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283403	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4597048	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39734	usd
	brli	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	183700	usd
	brli	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	638542	usd
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2020Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P180D
CY2020Q2	brli	Gross Proceed GrossProceed	6210000	usd
CY2020Q2	us-gaap	Cash Reserve Deposit Required And Made CashReserveDepositRequiredAndMade	6000000	usd
	brli	Aggregate Amounts AggregateAmounts	46000000	usd
	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	2069154	usd
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1610000	usd
	brli	Other Offering Cost OtherOfferingCost	459154	usd
CY2023Q2	us-gaap	Investments And Cash InvestmentsAndCash	67497	usd
CY2023Q2	brli	Fair Market Value Percentage FairMarketValuePercentage	0.80	pure
CY2023Q2	brli	Additional Price Per Share AdditionalPricePerShare	0.32
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.1
CY2021Q2	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2021Q3	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2022Q1	us-gaap	Shares Issued SharesIssued	633792	shares
CY2022Q1	brli	Aggregate Amounts AggregateAmounts	6529259	usd
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.3
CY2022Q1	us-gaap	Deposit Assets DepositAssets	101406	usd
CY2022Q1	brli	Aggregate Amount Shares AggregateAmountShares	633792	shares
CY2022Q3	brli	Aggregate Amount Shares AggregateAmountShares	1025281	shares
CY2022Q3	brli	Aggregate Amounts AggregateAmounts	10742906	usd
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.48
CY2022Q4	brli	Public Ordinary Per Share PublicOrdinaryPerShare	0.04
CY2022Q4	brli	Aggregate Amount Shares AggregateAmountShares	2375991	shares
CY2022Q4	brli	Aggregate Amounts AggregateAmounts	25180851	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.6
CY2022	brli	Redemption Of Share1 RedemptionOfShare1	1025281	shares
CY2022Q4	brli	Description Of Deposite DescriptionOfDeposite	On November 18, 2022, Nukkleus deposited $22,600 into the Trust Account, representing $0.04 per public ordinary share that was not redeemed in connection with extending the business combination completion window until November 23, 2022. On December 19, 2022, Nukkleus deposited $22,600 into the Trust Account, representing $0.04 per public ordinary share that was not redeemed in connection with extending the business combination completion window until January 23, 2023. On January 19, 2023, the shareholders of the Company approved the extension of the period of time the Company has to consummate its initial business combination from January 23, 2023 to up to not later than April 23, 2023, extendable by the Company on a monthly basis without further shareholder approval upon deposit of $0.04 per public ordinary share of the Company (the “Top-up Amount”). Notwithstanding the Top-up Amount, the Company undertook to increase the amount to be paid into the Trust Account for each monthly extension from $0.04 to $0.0525. Subsequently, the Company has committed to increase the amount to be paid into the Trust Account for any extension from February 23, 2023 to March 23, 2023 and from March 23, 2023 to April 23, 2023 to $0.08 per ordinary share outstanding. In connection with the extension, Nukkleus deposited $21,350 into the Trust Account, representing $0.0525 per public ordinary share that was not redeemed in connection with extending the business combination completion window until February 23, 2023. In connection with a special meeting to approve the extension of the business combination period, the Company’s shareholders elected to redeem an aggregate amount of 159,203 shares, and the Company redeemed such shares for an aggregate amount of $1,706,347, or approximately $10.72 per share
CY2023Q1	us-gaap	Deposit Assets DepositAssets	32500	usd
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q2	brli	Public Per Share PublicPerShare	0.08
CY2023Q2	us-gaap	Deposit Assets DepositAssets	32450	usd
	brli	Aggregate Amount Shares AggregateAmountShares	258	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2821	usd
CY2023Q2	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	10.93
CY2023Q2	us-gaap	Deposit Assets DepositAssets	32450	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q2	us-gaap	Deposit Assets DepositAssets	32450	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q2	us-gaap	Deposit Assets DepositAssets	32300	usd
	brli	Aggregate Amount Of Shares AggregateAmountOfShares	1779	shares
	brli	Aggregate Amounts AggregateAmounts	19837	usd
	brli	Aggregate Price Per Share AggregatePricePerShare	11.17
	brli	Redeemption Percent RedeemptionPercent	1	pure
	us-gaap	Other Expenses OtherExpenses	50000	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	67497	usd
CY2023Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	1572423	usd
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	32300	usd
	us-gaap	Trustee Fees TrusteeFees	32300	usd
CY2022	brli	Less Redemption Of Shares1 LessRedemptionOfShares1	10742905	shares
CY2022	brli	Redemption Of Share2 RedemptionOfShare2	2375991	shares
CY2022	brli	Less Redemption Of Shares2 LessRedemptionOfShares2	-25180851	shares
CY2022	brli	Add Accretion Of Carrying Value To Redemption Value AddAccretionOfCarryingValueToRedemptionValue	64950	shares
CY2022	brli	Reclassification Of Temporary Equity ReclassificationOfTemporaryEquity	1055394	shares
CY2022Q4	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	6055016	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	brli	Cash And Noncash Equivalents CashAndNoncashEquivalents	67497	usd
CY2022	brli	Cash And Noncash Equivalents CashAndNoncashEquivalents	55789	usd
CY2022Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	633792	shares
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1025281	shares
CY2022Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	2375991	shares
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	159203	shares
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	258	shares
	brli	Subject To Possible Redemption SubjectToPossibleRedemption	405475	shares
CY2022	brli	Subject To Possible Redemption SubjectToPossibleRedemption	564936	shares
	brli	Common Stock Per Share CommonStockPerShare	10
CY2021Q4	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	47387687	usd
CY2022	brli	Redemption Of Share RedemptionOfShare	633792	shares
CY2022	brli	Less Redemption Of Shares LessRedemptionOfShares	6529259	shares
	brli	Less Redemption Of Shares3 LessRedemptionOfShares3	-1706347	shares
	brli	Redemption Of Shares4 RedemptionOfShares4	258	shares
	brli	Less Redemption Of Shares4 LessRedemptionOfShares4	-2821	shares
	brli	Reclassifications Of Temporary To Permanent Equity1 ReclassificationsOfTemporaryToPermanentEquity1	183700	shares
CY2023Q2	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	4529548	usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-122363	usd
CY2022Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-35544	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-342866	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-495826	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1915531	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5477208	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1932251	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5755372	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
	us-gaap	Increase Decrease In Fair Value Of Price Risk Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1	460	usd
	brli	Business Combination BusinessCombination	P1Y
	brli	Ordinary Exceeds Per Share OrdinaryExceedsPerShare	12.5
	brli	Public Per Share Outstanding PublicPerShareOutstanding	0.04
CY2021Q4	brli	Trust Account Management Expense TrustAccountManagementExpense	1000	usd
CY2023Q1	brli	Trust Account Management Expense TrustAccountManagementExpense	500	usd
CY2022Q1	brli	Aggregate Of Shares AggregateOfShares	633792	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2821	usd
CY2023Q2	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	10.93
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32450	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32450	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32300	usd
CY2023Q2	us-gaap	Deposits Deposits	0.08	usd
	brli	Aggregate Of Shares AggregateOfShares	1779	shares
CY2023Q2	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	19837	usd
	brli	Aggregate Per Share AggregatePerShare	11.17
	brli	Working Capital WorkingCapital	1165600	usd
	us-gaap	Direct Operating Costs DirectOperatingCosts	195000	usd
	brli	Aggregate Amount AggregateAmount	1610000	usd
CY2023Q2	brli	Cash Fee Equal Percentage CashFeeEqualPercentage	0.01	pure
CY2020Q2	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	261000	shares
	us-gaap	Increase Decrease In Fair Value Of Price Risk Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1	61383	usd
	brli	Volatility Volatility	0.0318	pure
CY2022	brli	Volatility Volatility	0.034	pure
CY2023Q2	us-gaap	Share Price SharePrice	11.3
CY2022Q4	us-gaap	Share Price SharePrice	10.72
	brli	Expected Life Of The Warrants To Converts ExpectedLifeOfTheWarrantsToConverts	P5Y21D
CY2022	brli	Expected Life Of The Warrants To Converts ExpectedLifeOfTheWarrantsToConverts	P5Y2M23D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0417	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0404	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	180479	usd
CY2022Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	5041	usd
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	175438	usd
CY2022Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	56342	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	119096	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	10643	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-925	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	11568	usd
CY2023Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	1385	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	10183	usd
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.08
	brli	Aggregate Amount Of Shares AggregateAmountOfShares	1779	shares
CY2023Q2	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	19837	usd
CY2023Q2	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	11.17
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	us-gaap	Preferred Stock Shares Authorized Unlimited PreferredStockSharesAuthorizedUnlimited	Unlimited
CY2022	us-gaap	Preferred Stock Shares Authorized Unlimited PreferredStockSharesAuthorizedUnlimited	Unlimited
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q2	us-gaap	Marketable Securities MarketableSecurities		usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	000000
	dei	Entity Central Index Key EntityCentralIndexKey	0001787518

Files In Submission

Name	View Source	Status
0001213900-23-068964-index-headers.html	Edgar Link	pending
0001213900-23-068964-index.html	Edgar Link	pending
0001213900-23-068964.txt	Edgar Link	pending
0001213900-23-068964-xbrl.zip	Edgar Link	pending
brli-20230630.xsd	Edgar Link	pending
f10q0623ex31-1_brilliant.htm	Edgar Link	pending
f10q0623ex31-2_brilliant.htm	Edgar Link	pending
f10q0623ex32-1_brilliant.htm	Edgar Link	pending
f10q0623_brilliant.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
brli-20230630_def.xml	Edgar Link	unprocessable
brli-20230630_pre.xml	Edgar Link	unprocessable
brli-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
brli-20230630_cal.xml	Edgar Link	unprocessable
f10q0623_brilliant_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NUKK
Nukkleus Inc. Stock $nukk

2023 Q3 Form 10-Q Financial Statement

#000121390023068964 Filed on August 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUKK Nukkleus Inc. Stock $nukk

2023 Q3 Form 10-Q Financial Statement

#000121390023068964 Filed on August 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUKK
Nukkleus Inc. Stock $nukk